congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
A long-term phase 4 study to evaluate the risk of idiosyncratic hepatotoxicity associated with pexidartinib treatment
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Health-related quality of life from a phase 4 global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Pexidartinib upfront in a case study of tenosynovial giant cell tumor: Proof of concept for a treatment paradigm shift
Oral
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Pexidartinib use in patients with tenosynovial giant cell tumor: An analysis of the phase III randomized ENLIVEN clinical trial according to surgical history
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor (TGCT)
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Tumor response and regrowth in relation to clinical events among pexidartinib-treated patients in the phase 3 ENLIVEN trial